Form 4: Astera Labs Director Sells Shares via 10b5-1 Plan

Astera Labs Director Manuel Alba reported the sale of 32,000 common shares on December 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Manuel Alba, a Director of Astera Labs, Inc. (ALAB), reported multiple sales of common stock.
• A total of 32,000 shares were sold on December 1, 2025.
• The sales were executed automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025.
• Weighted average sale prices ranged from $153.7957 to $172.5747 per share across various transactions.
• Following these transactions, beneficial ownership includes 352,863 shares indirectly through Casa Alameda 2007, LLC, 1,574,498 shares indirectly through Alba Trust, 5,000 shares indirectly through his spouse, and 2,351 shares directly.
• Manuel Alba disclaims beneficial ownership of shares held by Casa Alameda 2007, LLC and Alba Trust, except to the extent of his pecuniary interest.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which is common for executives and directors for personal financial planning. It does not reflect new information about the company's performance or prospects.

Positives

• Sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating the transactions were scheduled in advance and not based on recent non-public information.

Negatives

• A director sold a significant number of shares (32,000), which could be interpreted as a reduction in insider conviction, although mitigated by the 10b5-1 plan.

Future Outlook

No specific future outlook or guidance is provided in this insider transaction report.

Management Comments

• The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Industry Context

This filing pertains to an individual director's stock transactions and does not provide broader industry context or trends.

Related Party Transactions

• Shares are owned indirectly by Casa Alameda 2007, LLC, where the Reporting Person is a manager.
• Shares are owned indirectly by Alba Trust, where the Reporting Person and his spouse are co-trustees.
• Shares are owned indirectly by the Reporting Person's spouse.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even if pre-planned, could be perceived by some as a slight negative signal, but the 10b5-1 plan mitigates concerns about opportunistic selling. The overall impact is likely minimal given the routine nature.

Key Dates

Recommendation

The filing details a routine insider sale executed under a Rule 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings without implying new material non-public information. This type of transaction typically has a neutral impact on the company's fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Astera Labs, ALAB, SEC Form 4, Insider Trading, Stock Sale, Manuel Alba, Director, 10b5-1 Plan, Beneficial Ownership, Equity Transaction